RudaCure Pursues Global Partnering for RCI001/RCI002 and Expanded Gene Therapy Co-Development at 2025 BIO-USA
RudaCure Inc. announced its participation in the **BIO International Convention (BIO-USA)** 2025 held in the United States, where it will conduct overseas licensing and co-development partnering meetings for its major pipelines: RCI001 (dry eye disease treatment) and **RCI002 (TRPV1-targeted analgesic)**.
At the event, RudaCure will meet with world-renowned ophthalmic pharmaceutical companies including Santen of Japan and Thea of France to share the development status and domestic/international clinical trial progress of RCI001, and conduct in-depth discussions on co-development and global market entry possibilities.
In the field of analgesic development, the company plans to present the research results and commercial potential of RCI002 to major global pharmaceutical companies. RCI002, a novel drug candidate that simultaneously targets TRPV1 and MOR (Mu-Opioid Receptor), has demonstrated potent analgesic effects at very low doses in preclinical studies, earning attention as a non-narcotic analgesic that overcomes the addiction and tolerance issues of opioid-based treatments. Various companies have shown strong interest, and this BIO-USA provides an important opportunity to explore specific licensing-out and co-development models.
RudaCure is currently also pursuing co-development of a gene therapy-based pain treatment for veterinary use, leveraging its proprietary ion channel-targeted peptide technology combined with AAV (Adeno-Associated Virus) vectors. This project, recently selected for the Ministry of Agriculture's Agri-Food Venture Development Program, is expected to serve as a platform technology applicable to both human and veterinary pharmaceuticals, and discussions with multiple overseas partners are expected to accelerate during BIO-USA.
CEO Yongho Kim stated, "BIO-USA 2025 will be a pivotal milestone for RudaCure's global expansion. Based on the clinical outcomes of RCI001 and the innovative mechanism of RCI002, we will proactively advance partnerships with global pharmaceutical companies and establish ourselves as a new drug developer with global presence."
